Our first product is a novel drug (new molecular entity) in a skin patch to treat Iron Deficiency Anemia, with significantly improved safety, efficacy and tolerability. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch.
Transdermal Iron Patch (NistuFe)
Iron deficiency is a hugely understated problem affecting 30 million people in the US alone and about 1.6 billion globally. The first line of treatment is oral iron supplements that are typically associated with poor absorption and tolerability with gastrointestinal (GI) side-effects ranging from mild to severe, for eg., stomach discomfort, nausea, constipation and diarrhea, oftentimes leading to patient non-compliance. The alternative standard-of-care is intravenous (IV) iron infusion which is more invasive, riskier due to a rare possibility of an anaphylactic shock, thereby requiring a clinical setting, and hence much more expensive than oral iron. Though IV iron has a greater bioavailability, the high payload of iron entering the systemic circulation also causes moderate to severe side-effects. There is no ideal solution comprising the benefits of both orals and IV, without their respective downsides. Keylika seeks to bridge this gap with its proprietary transdermal iron. Our patch will provide superior clinical outcomes, without adverse GI side-effects, at the convenience of a patient’s home.
Iron Deficiency Anemia (IDA)
Existing IDA Treatment: Suboptimal
Intravenous (IV) Iron Infusion
We have developed a platform synthesis technology for mixed ligand metal complexes that is used to generate a multitude of organometallic drugs for treating a wide range of therapeutic conditions: hematology, pain and inflammation, metabolic disorders to infectious diseases and oncology. We then administer these drugs using proven delivery technologies, to effect the best clinical outcomes. Positioned at the intersection of drug development and drug delivery, enables us to customize the molecular structure and/or formulation as well as add microsystems engineering elements, to optimize the drug delivery per clinical requirements.
Why others have failed:
Recently, we demonstrated definitive proof-of-concept in-vivo in rats to show excellent iron uptake, improvement of hematological parameters, and correction of the iron deficiency without any signs of systemic toxicity, by intradermal administration of our novel compound.
Buddhadev P. Chaudhuri, PhD
Frederik Ceyssens, PhD